Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors - PubMed (original) (raw)
Review
. 2001 Nov;21(11):1712-9.
doi: 10.1161/hq1101.098486.
Affiliations
- PMID: 11701455
- DOI: 10.1161/hq1101.098486
Review
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors
M Takemoto et al. Arterioscler Thromb Vasc Biol. 2001 Nov.
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors or statins are potent inhibitors of cholesterol biosynthesis. Several large clinical trials have demonstrated the beneficial effects of statins in the primary and secondary prevention of coronary heart disease. However, the overall clinical benefits observed with statin therapy appear to be greater than what might be expected from changes in lipid profile alone, suggesting that the beneficial effects of statins may extend beyond their effects on serum cholesterol levels. Indeed, recent experimental and clinical evidence indicates that some of the cholesterol-independent or "pleiotropic" effects of statins involve improving or restoring endothelial function, enhancing the stability of atherosclerotic plaques, and decreasing oxidative stress and vascular inflammation. Many of these pleiotropic effects of statins are mediated by their ability to block the synthesis of important isoprenoid intermediates, which serve as lipid attachments for a variety of intracellular signaling molecules. In particular, the inhibition of small GTP-binding proteins, Rho, Ras, and Rac, whose proper membrane localization and function are dependent on isoprenylation, may play an important role in mediating the direct cellular effects of statins on the vascular wall.
Similar articles
- Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
Liao JK. Liao JK. Am J Cardiol. 2005 Sep 5;96(5A):24F-33F. doi: 10.1016/j.amjcard.2005.06.009. Am J Cardiol. 2005. PMID: 16126020 Free PMC article. Review. - Pleiotropic effects of statins.
Liao JK, Laufs U. Liao JK, et al. Annu Rev Pharmacol Toxicol. 2005;45:89-118. doi: 10.1146/annurev.pharmtox.45.120403.095748. Annu Rev Pharmacol Toxicol. 2005. PMID: 15822172 Free PMC article. Review. - Direct vascular effects of HMG-CoA reductase inhibitors.
Laufs U, Liao JK. Laufs U, et al. Trends Cardiovasc Med. 2000 May;10(4):143-8. doi: 10.1016/s1050-1738(00)00044-x. Trends Cardiovasc Med. 2000. PMID: 11239793 Review. - Clinical implications for statin pleiotropy.
Liao JK. Liao JK. Curr Opin Lipidol. 2005 Dec;16(6):624-9. doi: 10.1097/01.mol.0000191913.16321.60. Curr Opin Lipidol. 2005. PMID: 16276239 Review. - Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.
Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J. Lahera V, et al. Curr Med Chem. 2007;14(2):243-8. doi: 10.2174/092986707779313381. Curr Med Chem. 2007. PMID: 17266583 Review.
Cited by
- Effects of statins on the risk of hepatocellular carcinoma.
Mansourian PG, Yoneda M, Krishna Rao M, Martinez FJ, Thomas E, Schiff ER. Mansourian PG, et al. Gastroenterol Hepatol (N Y). 2014 Jul;10(7):417-26. Gastroenterol Hepatol (N Y). 2014. PMID: 25904829 Free PMC article. - Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Neuhaus O, Stüve O, Zamvil SS, Hartung HP. Neuhaus O, et al. CNS Drugs. 2005;19(10):833-41. doi: 10.2165/00023210-200519100-00003. CNS Drugs. 2005. PMID: 16185093 - Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass.
Chello M, Mastroroberto P, Patti G, D'Ambrosio A, Morichetti MC, Di Sciascio G, Covino E. Chello M, et al. Heart. 2003 May;89(5):538-43. doi: 10.1136/heart.89.5.538. Heart. 2003. PMID: 12695460 Free PMC article. Clinical Trial. - Simvastatin normalizes qtc dispersion and reduces ventricular electrical instability in isolated hypercholesterolemia.
Gualdiero P, Esposito K, Ciotola M, Marfella R, Giugliano D. Gualdiero P, et al. J Endocrinol Invest. 2002 Jun;25(6):RC16-8. doi: 10.1007/BF03345487. J Endocrinol Invest. 2002. PMID: 12109633 Clinical Trial. - [Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hartung HP. Neuhaus O, et al. Nervenarzt. 2003 Aug;74(8):704-7. doi: 10.1007/s00115-003-1562-x. Nervenarzt. 2003. PMID: 12904873 Review. German.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous